Allurion Announces Strategic Distribution Partnership with Minogue Medical in Canada to Pioneer New Approach Focused on Metabolically Healthy Weight Loss
Minogue Medical has extensive experience in building high-performing medical networks across
鈥淲e select partners who share our vision for ethical, patient-centered care,鈥� said Danny Minogue, CEO of Minogue Medical. 鈥淎llurion鈥檚 commitment to clinical rigor complements our approach, and together, we intend to set a new benchmark in Canadian weight management.鈥�
Allurion is pioneering metabolically healthy weight loss, a new approach to obesity care focused on losing weight, keeping it off, and maintaining muscle. In partnership with Minogue Medical, Allurion will now be able to access providers who are committed to this approach and have demonstrated exceptional clinical results. In addition, the partnership is expected to increase access to providers offering a combination of the Allurion Program with GLP-1 therapy, to further enhance short and long-term results.
鈥淢inogue Medical has built a strong reputation in
鈥淭his agreement with Minogue Medical reflects our commitment to find partners globally who believe in our approach to obesity care,鈥� said Dr. Shantanu Gaur, Founder and CEO of Allurion. 鈥淲e are looking forward to working with Minogue to develop the Canadian market and establish a new standard of care in the treatment of obesity.鈥�
About Minogue Medical Inc.
Minogue Medical is a Canadian medical device distributor with deep expertise in the bariatric and metabolic health space. With a focus on ethical integration, clinician training, and long-term care pathways, Minogue supports a national network of medical professionals in delivering high-quality, patient-centered care.
About Allurion
Allurion is a pioneer in metabolically healthy weight loss. The Allurion Program is a weight-loss platform that combines the Allurion Gastric Balloon, the world鈥檚 first and only swallowable, ProcedurelessTM gastric balloon for weight loss, the Allurion Virtual Care Suite, including the Allurion Mobile App for consumers and Allurion Insights for healthcare providers featuring the Iris AI Platform, and the Allurion Connected Scale. The Allurion Virtual Care Suite is also available to providers separately from the Allurion Program to help customize, monitor, and manage weight-loss therapy for patients regardless of their treatment plan. The Allurion Gastric Balloon is an investigational device in
For more information about Allurion and the Allurion Virtual Care Suite, please visit .
Allurion is a trademark of Allurion Technologies, Inc. in
Forward-Looking Statements
This press release contains forward-looking statements that reflect Allurion鈥檚 beliefs and assumptions based on information currently available. In some cases, you can identify forward-looking statements by the following words: 鈥渕ay,鈥� 鈥渨ill,鈥� 鈥渃ould,鈥� 鈥渨ould,鈥� 鈥渟hould,鈥� 鈥渆xpect,鈥� 鈥渋ntend,鈥� 鈥減lan,鈥� 鈥渁nticipate,鈥� 鈥渂elieve,鈥� 鈥渆stimate,鈥� 鈥減redict,鈥� 鈥減roject,鈥� 鈥減otential,鈥� 鈥渃ontinue,鈥� 鈥渙ngoing鈥� or the negative of these terms or other comparable terms, although not all forward-looking statements contain these words. Although Allurion believes it has a reasonable basis for each forward-looking statement contained in this release, these statements involve risks and uncertainties that may cause actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements.
Forward-looking statements in this press release include, but are not limited to, statements regarding: establishing a new standard for weight loss; choosing appropriate partners; pioneering inability healthy weight loss; the uniqueness of Allurion鈥檚 product and service offerings, including the Allurion Program; and other statements about future events that reflect the current beliefs and assumptions of Allurion鈥檚 management based on information currently available to management.
Allurion cannot assure you that the forward-looking statements in this press release will prove to be accurate. These forward looking statements are subject to a number of risks and uncertainties, including, among others, general economic, political and business conditions; the ability of Allurion to obtain and maintain regulatory approval for, and successfully commercialize, the Allurion Program, including the Allurion Balloon; the timing of, and results from, Allurion鈥檚 clinical studies and trials, including with respect to the combination of GLP-1s with the Allurion Balloon; the evolution of the markets in which Allurion competes, including the impact of GLP-1 drugs; the ability of Allurion to maintain its listing on the New York Stock Exchange; a changing regulatory landscape in the highly competitive industry in which Allurion competes; the impact of the imposition of current and potential tariffs and trade negotiations, and those factors discussed under the heading 鈥淩isk Factors鈥� in the Company's Annual Report on Form 10-K filed with the Securities and Exchange Commission (鈥淪EC鈥�) on March 27, 2025, and updated from time to time by its other filings with the SEC, and its Quarterly Report on Form 10-Q filed with the SEC on May 15, 2025. Undue reliance should not be placed on forward-looking statements, which speak only as of the date they are made. Allurion undertakes no obligation to update any forward-looking statements to reflect any new information, events, or circumstances after the date they are made, or to reflect the occurrence of unanticipated events, other than as required by applicable law.
View source version on businesswire.com:
Media
Allurion Press Office
Woodrow Communications
[email protected]
Investor
[email protected]
Source: Allurion Technologies, Inc.
